A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback